Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is used to treat primary open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog that reduces intra‑ocular pressure in glaucoma‑related conditions. - Primary open‑angle glaucoma: lowers pressure to prevent optic nerve damage. - Ocular hypertension: reduces elevated eye pressure to lower risk of developing glaucoma.

Latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting clarity. - Allergic reaction: swelling, itching, or rash around the eye. - Paradoxical rise in intra‑ocular pressure. - Darkening of peri‑ocular skin. - Vision loss: sudden decrease in visual acuity.

Before using Latanoprost, consider the following safety measures. - Monitor intra‑ocular pressure: ensure therapeutic reduction is achieved. - Assess for ocular infections: avoid use if active infection is present. - Avoid in active ocular inflammation: may exacerbate condition. - Caution in hypersensitivity: discontinue if allergic signs appear. - Pregnancy and lactation: safety unknown; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analogs: may increase pigmentary changes. - Use with ocular corticosteroids: potential reduction in efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may diminish pressure‑lowering effect. - Systemic beta‑blockers: additive hypotensive effect may occur. - Contact lens wear: may affect drug absorption and cause irritation.